USNA
USANA Health Sciences, Inc. NYSE Listed Apr 4, 1994$19.50
Mkt Cap $359.9M
52w Low $16.60
13.4% of range
52w High $38.32
50d MA $18.48
200d MA $22.65
P/E (TTM)
33.4x
EV/EBITDA
2.4x
P/B
0.6x
Debt/Equity
0.0x
ROE
2.0%
P/FCF
42.4x
RSI (14)
—
ATR (14)
—
Beta
0.70
50d MA
$18.48
200d MA
$22.65
Avg Volume
129.3K
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
3838 West Parkway Boulevard · Salt Lake City, UT 84120 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.44 | 0.41 | -6.8% | 19.26 | +3.8% | +3.9% | -2.7% | — | — | — | — |
| Feb 17, 2026 | AMC | 0.41 | 0.60 | +46.3% | 20.66 | +9.0% | -8.0% | +8.2% | +5.5% | +0.7% | -0.7% | — |
| Oct 21, 2025 | AMC | 0.25 | -0.15 | -160.0% | 21.03 | +0.0% | -0.6% | -1.3% | +0.8% | -3.4% | +1.1% | — |
| Jul 22, 2025 | AMC | 0.54 | 0.74 | +37.0% | 31.53 | +17.3% | +12.4% | -9.4% | -0.4% | -1.6% | -3.8% | — |
| Apr 22, 2025 | AMC | 0.70 | 0.73 | +4.3% | 24.24 | +5.2% | +4.9% | +6.6% | +0.3% | +1.3% | +1.3% | — |
| Feb 25, 2025 | AMC | 0.49 | 0.64 | +30.6% | 31.96 | +11.6% | +3.9% | -13.8% | +3.3% | +1.3% | -1.3% | — |
| Oct 22, 2024 | AMC | 0.49 | 0.56 | +14.3% | 34.48 | -0.3% | +6.1% | +3.4% | -2.6% | +1.3% | +0.0% | — |
| Jul 23, 2024 | AMC | 0.65 | 0.54 | -16.9% | 45.96 | -11.9% | -3.2% | -6.0% | +1.9% | +1.8% | +0.8% | — |
| Apr 30, 2024 | AMC | 0.69 | 0.86 | +24.6% | 41.52 | +7.6% | +9.7% | +3.4% | -3.3% | -2.1% | +0.3% | — |
| Feb 6, 2024 | AMC | 0.52 | 0.87 | +67.3% | 47.80 | +9.0% | +4.0% | +2.3% | +0.1% | +2.9% | -6.3% | — |
| Oct 24, 2023 | AMC | 0.64 | 0.59 | -7.8% | 55.43 | -9.8% | -18.0% | +1.6% | -2.8% | +2.9% | -1.4% | — |
| Jul 25, 2023 | AMC | 0.70 | 0.89 | +27.1% | 63.39 | +2.4% | +7.1% | -2.9% | -1.2% | -0.3% | -1.5% | — |
| Apr 25, 2023 | AMC | 0.77 | 0.95 | +23.4% | 62.61 | +4.1% | +8.4% | -1.1% | -1.2% | +0.9% | +0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 | DA Davidson | Maintains | Neutral → Neutral | — | $33.21 | $33.21 | +0.0% | -13.8% | +3.3% | +1.3% | -1.3% | +4.3% |
| Jan 2 | DA Davidson | Maintains | Neutral → Neutral | — | $35.89 | $36.59 | +2.0% | +1.4% | -0.6% | -3.3% | +0.9% | -1.1% |
| Oct 23 | DA Davidson | Maintains | Neutral → Neutral | — | $34.48 | $34.37 | -0.3% | +6.1% | +3.4% | -2.6% | +1.3% | +0.0% |
| Jul 25 | DA Davidson | Maintains | Neutral → Neutral | — | $44.49 | $44.35 | -0.3% | -6.0% | +1.9% | +1.8% | +0.8% | +2.0% |
| May 7 | DA Davidson | Maintains | Neutral → Neutral | — | $44.61 | $44.76 | +0.3% | +0.3% | +0.6% | +2.9% | +0.8% | +1.2% |
| Feb 22 | DA Davidson | Maintains | Neutral → Neutral | — | $49.30 | $48.74 | -1.1% | -1.8% | +0.8% | -0.5% | -0.8% | -0.1% |
| Oct 25 | DA Davidson | Maintains | Neutral → Neutral | — | $55.43 | $49.98 | -9.8% | -18.0% | +1.6% | -2.8% | +2.9% | -1.4% |
| Apr 26 | DA Davidson | Maintains | Neutral → Neutral | — | $62.61 | $65.20 | +4.1% | +8.4% | -1.1% | -1.2% | +0.9% | +0.4% |
| Feb 13 | DA Davidson | Maintains | Neutral → Neutral | — | $61.13 | $60.84 | -0.5% | -0.0% | -0.5% | +2.6% | -0.3% | +0.2% |
| Oct 27 | DA Davidson | Maintains | Neutral → Neutral | — | $56.84 | $56.04 | -1.4% | -3.2% | +0.4% | -4.9% | +2.4% | -4.7% |
| Jul 28 | DA Davidson | Maintains | Neutral → Neutral | — | $69.42 | $69.46 | +0.1% | +1.1% | -0.8% | +0.5% | -0.7% | +1.9% |
| Jul 12 | DA Davidson | Maintains | Neutral → Neutral | — | $65.94 | $65.66 | -0.4% | +2.3% | -0.3% | -3.2% | +2.8% | -1.1% |
| Jul 7 | Jefferies | Downgrade | Hold → Underperform | — | $76.51 | $69.00 | -9.8% | -12.4% | -0.3% | -1.4% | +2.3% | -0.3% |
| Apr 27 | DA Davidson | Maintains | Neutral → Neutral | — | $75.52 | $74.78 | -1.0% | +0.5% | +1.2% | -0.3% | +0.2% | +0.4% |
| Apr 14 | DA Davidson | Maintains | Neutral → Neutral | — | $82.85 | $82.93 | +0.1% | -0.9% | -3.4% | +1.6% | +1.0% | -2.0% |
| Feb 10 | Roth Capital | Maintains | Buy → Buy | — | $87.16 | $95.86 | +10.0% | +13.0% | -5.3% | -2.9% | +1.5% | -0.3% |
| Dec 17 | Roth Capital | Maintains | Buy → Buy | — | $78.42 | $79.47 | +1.3% | -0.1% | +0.7% | -1.0% | -0.8% | +1.5% |
| Aug 22 | Jefferies | Maintains | Hold → Hold | — | $67.49 | $66.78 | -1.1% | -1.7% | -3.1% | +2.0% | -0.2% | +1.3% |
| Jul 3 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $76.72 | $63.39 | -17.4% | -19.4% | -0.4% | +0.8% | -3.2% | +1.1% |
| Apr 16 | Tigress Financial | Maintains | Buy → Buy | — | $84.72 | $85.12 | +0.5% | -0.4% | -1.3% | -1.2% | -0.7% | +0.7% |
| Apr 23 | Pivotal Research | Downgrade | Buy → Hold | — | $100.35 | $100.35 | +0.0% | -4.6% | +0.3% | +11.2% | -2.5% | +1.4% |
| Jan 24 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $76.60 | $75.20 | -1.8% | -0.1% | +0.0% | -0.3% | -0.9% | -0.1% |
| May 3 | Pivotal Research | Upgrade | Hold → Buy | — | $56.40 | $55.95 | -0.8% | +5.5% | +3.1% | +3.3% | +0.0% | +0.5% |
| May 1 | Pivotal Research | Downgrade | Buy → Hold | — | $56.85 | $56.90 | +0.1% | -1.8% | +1.0% | +5.5% | +3.1% | +3.3% |
| Feb 10 | DA Davidson | Downgrade | Buy → Neutral | — | $59.77 | $48.75 | -18.4% | -20.7% | +3.4% | +6.6% | +0.5% | +4.6% |
| Sep 16 | DA Davidson | Upgrade | Neutral → Buy | — | $69.31 | $70.02 | +1.0% | +2.8% | +2.5% | -3.1% | +0.4% | +0.4% |
| Aug 6 | DA Davidson | Downgrade | Buy → Neutral | — | $88.06 | $86.28 | -2.0% | -10.9% | +2.0% | +2.5% | -1.3% | -0.8% |
| Jun 26 | DA Davidson | Maintains | Buy → Buy | — | $68.92 | $69.50 | +0.8% | +0.1% | +0.8% | -1.7% | +5.2% | -1.4% |
| Apr 27 | Pivotal Research | Downgrade | Buy → Hold | — | $64.14 | $64.11 | -0.1% | -3.4% | +0.6% | -4.8% | -4.1% | +5.7% |
| Oct 20 | Pivotal Research | Maintains | Buy → Buy | — | $40.18 | $40.76 | +1.4% | +2.9% | +4.0% | +0.4% | -1.2% | +0.5% |
| Oct 17 | Canaccord Genuity | Maintains | Hold → Hold | — | $40.02 | $40.51 | +1.2% | +0.4% | +2.9% | +4.0% | +0.4% | -1.2% |
| Nov 8 | Sidoti & Co. | Upgrade | Neutral → Buy | — | $33.80 | $34.27 | +1.4% | +4.9% | -2.1% | -0.9% | +1.3% | -1.3% |
| Jul 24 | DA Davidson | Maintains | Neutral → Neutral | — | $40.27 | $40.49 | +0.5% | -8.1% | +4.4% | +1.8% | +0.4% | +3.3% |
| May 30 | DA Davidson | Downgrade | Buy → Neutral | — | $34.73 | $34.70 | -0.1% | +0.7% | +0.3% | -4.0% | -1.2% | -2.3% |
| Feb 7 | Wedbush | Upgrade | Underperform → Neutral | — | $18.96 | $19.35 | +2.0% | +8.3% | -0.5% | +4.7% | -1.2% | +0.2% |
| Dec 17 | Canaccord Genuity | Downgrade | Buy → Hold | — | $19.21 | $18.83 | -2.0% | -0.5% | +2.1% | -5.2% | -4.1% | -4.7% |
| Oct 24 | DA Davidson | Maintains | Buy → Buy | — | $23.48 | $24.74 | +5.3% | -0.6% | -5.5% | +0.4% | -2.5% | +1.8% |
| Oct 24 | Wedbush | Maintains | Underperform → Underperform | — | $23.48 | $24.74 | +5.3% | -0.6% | -5.5% | +0.4% | -2.5% | +1.8% |
| Jul 31 | Canaccord Genuity | Upgrade | Hold → Buy | — | $22.50 | $22.50 | +0.0% | -0.0% | -2.5% | +2.4% | +0.9% | +2.7% |
| Apr 24 | DA Davidson | Maintains | Buy → Buy | — | $18.36 | $18.27 | -0.5% | +0.2% | +11.4% | -1.5% | +1.3% | +2.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | Foukas JoshuaOff | CHIEF LEGAL OFFICER | Sell | 3,791 | $19.82 | $75K | — | — | — |
8-K · 7.01
! Medium
USANA Health Sciences Inc -- 8-K 7.01: Regulation FD Disclosure
USANA disclosed material information via Regulation FD, signaling the company may face regulatory scrutiny or competitive pressures that could impact its direct-selling business model and revenue growth trajectory.
Feb 18
8-K · 5.02
!!! Very High
USANA Health Sciences Inc -- 8-K 5.02: Executive Change
USANA Health Sciences' CEO Jim Brown resigned, creating leadership uncertainty that could impact strategic direction and investor confidence in the direct-sales nutrition company.
Feb 11
Data updated apr 27, 2026 7:08am
· Source: massive.com